title: Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients.
abstract: Resistin, which appears to be related to insulin resistance, is secreted mainly from macrophages in human and some of its polymorphisms have been reported. Based on recent in vitro studies, resistin may be associated with atherosclerosis by mediating endothelial hyperactivity. We investigated whether resistin polymorphism at -420C>G is associated with serum resistin levels and diabetic macroangiopathy (coronary heart disease, arteriosclerosis obliterans, and stroke) in 349 Japanese type 2 diabetic patients (DM) and 286 non-diabetic controls (non-DM). Serum resistin levels in DM with a history of stroke were significantly higher than those without, 19.6+/-2.1 and 12.4+/-0.5 ng/ml (P<0.001), respectively. Furthermore, the levels were significantly increased in a genotype-dependent manner (CC, CG, GG) based on the polymorphism at -420C>G (P<0.001) in both DM and non-DM. The prevalence of stroke in DM significantly increased according to the presence of mutations (P<0.035). In multivariate logistic-regression analysis, individuals with the CG or GG genotypes were significantly more likely to have had a stroke than individuals with the CC genotype (vs. CG; OR 2.99, P=0.024, vs. GG; OR 4.49, P=0.010). These data suggested that the genotyping of resistin polymorphism at -420(C>G) can be a risk marker for stroke susceptibility in Japanese type 2 diabetic patients.
authors.affiliation: Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Tsukahara
authors.forename: Eitaro
authors.initials: E
authors.lastname: Nakashima
authors.forename: Atsuko
authors.initials: A
authors.lastname: Watarai
authors.forename: Yoji
authors.initials: Y
authors.lastname: Hamada
authors.forename: Keiko
authors.initials: K
authors.lastname: Naruse
authors.forename: Hideki
authors.initials: H
authors.lastname: Kamiya
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Nakamura
authors.forename: Norihiro
authors.initials: N
authors.lastname: Kato
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hamajima
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Sekido
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Niwa
authors.forename: Makoto
authors.initials: M
authors.lastname: Tomita
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Oiso
authors.forename: Jiro
authors.initials: J
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000235:genetics; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012016:Reference Values; D052243:Resistin / Q000097:blood / Q000235:genetics*; D020521:Stroke / Q000453:epidemiology / Q000235:genetics
chemical_list: D015415:Biomarkers; D006442:Glycated Hemoglobin; D052243:Resistin